دورية أكاديمية
أعرض في EDS

Reduction of anterior uveitis flares in patients with axial spondyloarthritis on certolizumab pegol treatment: final 2-year results from the multicenter phase IV C-VIEW study.

التفاصيل البيبلوغرافية
العنوان: Reduction of anterior uveitis flares in patients with axial spondyloarthritis on certolizumab pegol treatment: final 2-year results from the multicenter phase IV C-VIEW study.
المؤلفون: van der Horst-Bruinsma IE; Department of Rheumatology, Amsterdam University Medical Center, Location VU Medical Center, De Boelelaan 1117, Amsterdam, 1081 HV, The Netherlands., van Bentum RE; Department of Rheumatology, Amsterdam University Medical Centers, Location VU Medical Centre, Amsterdam, The Netherlands., Verbraak FD; Department of Ophthalmology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands., Deodhar A; Division of Arthritis and Rheumatic Diseases, Oregon Health and Science University, Portland, OR, USA., Rath T; Department of Opthalmology, St Franziskus-Hospital, Münster, Germany., Hoepken B; UCB Pharma, Monheim am Rhein, Germany., Irvin-Sellers O; UCB Pharma, Slough, UK., Thomas K; UCB Pharma, Monheim am Rhein, Germany., Bauer L; UCB Pharma, Monheim am Rhein, Germany., Rudwaleit M; Clinic for Internal Medicine and Rheumatology, Klinikum Bielefeld and Department of Gastroenterology, Infectiology and Rheumatology, Charité Berlin, Germany.
المصدر: Therapeutic advances in musculoskeletal disease [Ther Adv Musculoskelet Dis] 2021 Mar 29; Vol. 13, pp. 1759720X211003803. Date of Electronic Publication: 2021 Mar 29 (Print Publication: 2021).
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Sage Country of Publication: England NLM ID: 101517322 Publication Model: eCollection Cited Medium: Print ISSN: 1759-720X (Print) Linking ISSN: 1759720X NLM ISO Abbreviation: Ther Adv Musculoskelet Dis Subsets: PubMed not MEDLINE
أسماء مطبوعة: Publication: - : London : Sage
Original Publication: Oct. 2009- : Thousand Oaks, CA : Sage Publications
مستخلص: Introduction: Acute anterior uveitis (AAU), affecting up to 40% of patients with axial spondyloarthritis (axSpA), risks permanent visual deficits if not adequately treated. We report 2-year results from C-VIEW, the first study to prospectively investigate certolizumab pegol (CZP) on AAU in patients with active axSpA at high risk of recurrent AAU.
Patients and Methods: C-VIEW (NCT03020992) was a 104-week (96 weeks plus 8-week safety follow-up), open-label, multicenter study. Eligible patients had active axSpA, human leukocyte antigen-B27 (HLA-B27) positivity and a history of recurrent AAU (⩾2 AAU flares in total; ⩾1 in the year prior to baseline). Patients received CZP 400 mg at weeks 0, 2 and 4, then 200 mg every 2 weeks to week 96. The primary efficacy endpoint was the AAU flare event rate during 96 weeks' CZP versus 2 years pre-baseline.
Results: Of 115 enrolled patients, 89 initiated CZP (male: 63%; radiographic/non-radiographic axSpA: 85%/15%; mean disease duration: 9.1 years); 83 completed week 96. There was a significant 82% reduction in AAU flare event rate during CZP versus pre-baseline [rate ratio (95% confidence interval): 0.18 (0.12-0.28), p  < 0.001]. One hundred percent and 59.6% of patients experienced ⩾1 and ⩾2 AAU flares pre-baseline, respectively, compared to 20.2% and 11.2% during treatment. Age, sex and axSpA population subgroup analyses were consistent with the primary analysis. There were substantial improvements in axSpA disease activity with no new safety signal identified.
Conclusion: CZP treatment significantly reduced AAU flare event rate in patients with axSpA and a history of AAU, indicating CZP is a suitable treatment option for patients at risk of recurrent AAU.
Trial Registration Clinicaltrialsgov: NCT03020992, URL: https://clinicaltrials.gov/ct2/show/NCT03020992.
Competing Interests: Conflict of interest statement: Irene E. van der Horst-Bruinsma: Honoraria/consulting fees/research grants from AbbVie, BMS, MSD, Novartis, Pfizer, UCB Pharma; Rianne E. van Bentum: none; Frank D. Verbraak: Honoraria/consulting fees/research grants from Bayer, Novartis, IDxDR, UCB Pharma; Atul Deodhar: Honoraria/consulting fees/research grants from AbbVie, Amgen, Boehringer Ingelheim, BMS, Eli Lilly, GSK, Janssen, Novartis, Pfizer, UCB Pharma; Thomas Rath: Honoraria/consulting fees from AbbVie, BMS, Chugai, Eli Lilly, MSD, Novartis, Pfizer, Roche, UCB Pharma; Bengt Hoepken, Oscar Irvin-Sellers, Lars Bauer: Employees of UCB Pharma; Karen Thomas: Former contractor with UCB Pharma; Martin Rudwaleit: Honoraria/consulting fees from AbbVie, BMS, Celgene, Eli Lilly, Janssen, MSD, Novartis, Pfizer, Roche, UCB Pharma.
(© The Author(s), 2021.)
References: Eye Sci. 2012 Dec;27(4):169-72. (PMID: 23225836)
Semin Arthritis Rheum. 2020 Aug;50(4):687-694. (PMID: 32521322)
Rheumatology (Oxford). 2017 Sep 1;56(9):1498-1509. (PMID: 28498975)
Ann Rheum Dis. 2017 Sep;76(9):1515-1521. (PMID: 28254789)
Rheumatology (Oxford). 2017 Dec 1;56(12):2060-2067. (PMID: 28340205)
J Rheumatol. 2019 Feb;46(2):153-159. (PMID: 30385705)
Ann Rheum Dis. 2016 May;75(5):795-810. (PMID: 26888948)
Clin Exp Rheumatol. 2019 Jan-Feb;37(1):26-31. (PMID: 30620268)
Ther Adv Musculoskelet Dis. 2020 Sep 12;12:1759720X20951733. (PMID: 32963592)
Ann Rheum Dis. 2008 Jul;67(7):955-9. (PMID: 17962239)
Biomed Res Int. 2018 Oct 14;2018:9460187. (PMID: 30406148)
Ophthalmol Retina. 2017 May - Jun;1(3):179-180. (PMID: 31047418)
Ann Rheum Dis. 2006 Dec;65(12):1631-4. (PMID: 16901960)
Arthritis Res Ther. 2016 Sep 01;18:196. (PMID: 27586785)
Ann Rheum Dis. 2009 Jun;68(6):777-83. (PMID: 19297344)
RMD Open. 2020 Apr;6(1):. (PMID: 32371433)
Rheumatology (Oxford). 2018 Jun 1;57(6):959-968. (PMID: 29029331)
Arthritis Rheum. 2009 Mar;60(3):717-27. (PMID: 19248087)
Arthritis Rheumatol. 2019 Jul;71(7):1101-1111. (PMID: 30848558)
Clin Exp Optom. 2007 Mar;90(2):70-82. (PMID: 17311570)
Clin Exp Rheumatol. 2002 Nov-Dec;20(6 Suppl 28):S143-5. (PMID: 12463466)
Arthritis Rheum. 2005 Aug;52(8):2447-51. (PMID: 16052578)
Arthritis Care Res (Hoboken). 2016 Jun;68(6):838-44. (PMID: 26815944)
J Rheumatol. 2017 Sep;44(9):1347-1354. (PMID: 28668811)
Ann Rheum Dis. 2014 Jan;73(1):39-47. (PMID: 24013647)
Arthritis Care Res (Hoboken). 2019 Oct;71(10):1285-1299. (PMID: 31436026)
Ann Rheum Dis. 2009 May;68(5):696-701. (PMID: 18662932)
Arthritis Rheum. 2012 May;64(5):1407-11. (PMID: 22139851)
J Rheumatol. 2014 Sep;41(9):1843-8. (PMID: 25086071)
Ann Rheum Dis. 2017 Jun;76(6):978-991. (PMID: 28087505)
Semin Arthritis Rheum. 2016 Aug;46(1):95-101. (PMID: 27060872)
فهرسة مساهمة: Keywords: TNF inhibitor*; axial spondyloarthritis*; extra-articular manifestations*; uveitis*
سلسلة جزيئية: ClinicalTrials.gov NCT03020992
تواريخ الأحداث: Date Created: 20210415 Latest Revision: 20220422
رمز التحديث: 20240628
مُعرف محوري في PubMed: PMC8010825
DOI: 10.1177/1759720X211003803
PMID: 33854572
قاعدة البيانات: MEDLINE
الوصف
تدمد:1759-720X
DOI:10.1177/1759720X211003803